<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892944</url>
  </required_header>
  <id_info>
    <org_study_id>D2080C00009</org_study_id>
    <nct_id>NCT00892944</nct_id>
  </id_info>
  <brief_title>An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516</brief_title>
  <official_title>An Open Label Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2516 After Oral Administration to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if AZD2516 binds to mGluR5 receptors in the brain.
      This will then help to make accurate predictions of efficacy and dosing in the future
      development programme.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron emission tomography to determine if AZD2516 can displace the radioligand [11C]AZ12713580 and describe relationship between AZD2516 exposure and mGluR5 receptor occupancy</measure>
    <time_frame>1 Month: Baseline and 3 PET examinations</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AZD2516 by adverse events, vitals signs, ECG, body temperature and laboratory variables</measure>
    <time_frame>Assessed at each visit from baseline to follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the Pharmacokinetics of AZD2516</measure>
    <time_frame>1 Month: 3 doses AZD2516 and 16 planned PK samples after each dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2516</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2516</intervention_name>
    <description>Fractionated single oral dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal MRI scan

          -  Healthy male or non-fertile females

          -  Body Mass Index (BMI) of ≥19 to ≤28 kg/m2 and weight of ≥50 to ≤100 kg

        Exclusion Criteria:

          -  History of disease or condition that may interfere with the objectives of the study

          -  History of previous or ongoing psychiatric disease/condition

          -  Concomitant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingemar Bylesjo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael O'Malley</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2009</study_first_posted>
  <last_update_submitted>October 27, 2009</last_update_submitted>
  <last_update_submitted_qc>October 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>AZD2516</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

